MedTrace Logo

The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine

NCT03566472 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-06-11

No results posted yet for this study

Summary

Glargine is commonly used in insulin supplemental therapy in patients with type 2 diabetes(T2D) at present. This study aims to investigate the current status of blood glucose control in patients with T2D treated with glargine. Glycated hemoglobin(HbA1c) will be tested in these patients to assess the blood glucose control and Continuous Glucose Monitoring System (CGMS) will be used to investigate the glucose variability. Islet function, duration of diabetes, complications, exercise, insulin dose, oral medication regimen and insulin antibodies will be recorded in detail. This study will analysis the association between these clinical characteristics and blood glucose control.

Conditions

  • Type2 Diabetes

Interventions

DIAGNOSTIC_TEST

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System for 72 hours

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Ma Jianhua · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-12
Primary Completion
2018-12-30
Completion
2019-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566472 on ClinicalTrials.gov